| |
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE 2006
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended
30th June2006
(Un Audited) |
Year ended
31st March 2006
(Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
18 |
Sales (net)
Income from Potential patent infringment suit
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Materials Consumed
c) Staff Cost
d) Other Expenditure
Profit before R&D, Interest & Depreciation(1+2+3-4)
Research and Development Expenditure
Interest
Depreciation
Profit before Tax (5-6-7-8)
Provision for Tax
Profit after Tax before Minority Interest and share in Associates (9-10)
Less : Minority Interest
Less : Share of loss in Associate
Net Profit (11-12-13)
Equity Capital
Reserves excluding revaluation reserves
E.P.S (Face value - Rs.2/-)
- Basic - Not annualised
Annualised
- Diluted - Not annualised
Annualised
Aggregate of Non Promoters' Shareholding
Number of shares - Face value of Rs.2 / - each.
Percentage of Shareholding
|
4,421.60
66.91
72.62
3,709.06
456.46
2,122.28
455.17
675.15
852.07
177.02
156.91
137.30
380.84
25.16
355.68
(15.16)
(2.50)
338.02
307.33
-
2.20
8.80
2.15
8.60
68789725
44.77%
|
11,586.15
268.39
1,400.81
9,876.01
(293.27)
7,070.38
1,210.36
1,888.54
3,379.34
393.73
268.84
335.05
2,381.72
376.09
2,005.63
(6.16)
(7.42)
1,992.05
307.26
9,420.63
-
13.23
-
12.99
68750750
44.75%
|
|
Segment Information :
Segment Revenue :
- Pharmaceuticals
- Medical Supplies
Less: Inter segment Revenue
Net Segment Revenue
Segment Results :
Profit before tax and interest from each segment
- Pharmaceuticals
- Medical Supplies
Total
Less: Interest
Other unallocable Income /(Expenditure)
Total Profit before tax
Capital Employed :
- Pharmaceuticals
- Medical Supplies
- Unallocable
Total Capital Employed
|
3,975.47
615.23
(169.10)
4,421.60
365.44
32.78
398.22
(156.91)
139.53
380.84
12,318.00
261.74
11,517.41
24,097.15
|
10,132.88
1,611.53
(158.26)
11,586.15
1,212.35
75.90
1,288.25
(268.84)
1,362.31
2,381.72
7,840.72
178.68
14,614.55
22,633.95
|
|
| Notes : |
- The above results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 27th July 2006, and subject to limited review by Statutory Auditors.
- The above results include the financials of Subsidiaries - Docpharma NV , Mchem Group, China and Concord Biotech Limited, India and Joint Ventures - Astrix Laboratories Limited, India and Fine Chemical Corporation, South Africa .
- The previous quarter figures are not given as the same is not applicable.
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 27th July 2006 |
Sd/-
N.PRASAD
Executive Chairman
|
|
UN AUDITED FINANCIAL RESULTS
FOR
THE QUARTER ENDED 30TH JUNE 2006
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 30th June |
Year ended
31st March 2006
(Audited) |
| 2006 (Un Audited) |
2005 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15. |
Sales (net)
- Exports
- Domestic
Income from Potential patent infringment suit
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Materials Consumed
c) Staff Cost
d) Other Expenditure
Profit before R&D, Interest & Depreciation(1+2+3-4)
Research and Development Expenditure
Interest
Depreciation
Profit before Tax (5-6-7-8)
Provision for Tax
Profit after Tax (9-10)
Equity Capital
Reserves excluding revaluation reserves
E.P.S (Face value - Rs.2/-)
- Basic - Not annualised
Annualised
- Diluted - Not annualised
Annualised
Aggregate of Non Promoters' Shareholding
Number of shares - Face value of Rs.2 / - each.
Percentage of Shareholding
|
1941.21
1158.78
782.43
66.91
76.23
1542.43
439.44
687.01
155.69
260.29
541.92
140.42
31.72
58.06
311.72
22.00
289.72
307.33
-
1.89
7.56
1.84
7.36
68789725
44.77%
|
1543.37
705.32
838.05
66.91
111.27
1320.25
(23.83)
930.90
110.67
302.51
401.30
52.72
10.75
53.89
283.94
31.00
252.94
299.47
-
1.69
6.76
1.68
6.72
51904520
34.66%
|
6671.36
3959.88
2711.48
268.39
1317.26
5523.71
(167.83)
4029.84
480.00
1181.70
2733.30
311.19
81.50
223.42
2117.19
293.39
1823.80
307.26
8333.87
-
12.11
-
11.89
68750750
44.75%
|
|
| Notes : |
- The above results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 27th July 2006, and subject to limited review by Statutory Auditors.
- The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
- 38,975 Equity shares of Rs.2/- each at a premium of Rs.141.13 were allotted during the quarter, on exercise of stock options under the Employees Stock Option Scheme.
- Pursuant to the Accounting Standard 15 (Revised) on ‘Employee Benefits’ (AS-15) issued by the Institute of Chartered Accountants of India being mandatory with effect from 1st April 2006, the Company has debited an additional amount of Rs 15.06 Millions in Staff Cost, for the quarter ended June 30, 2006. The additional obligation of the Company as on March 31, 2006 amounting to Rs 21.37 Millions, net of deferred tax (Rs 10.84 Millions), has in accordance with the transitional provisions of AS -15 been debited to the retained earnings.
- Pursuant to the Accounting Standard 15 (Revised) on ‘Employee Benefits’ (AS-15) issued by the Institute of Chartered Accountants of India being mandatory with effect from 1st April 2006, the Company has debited an additional amount of Rs 15.06 Millions in Staff Cost, for the quarter ended June 30, 2006. The additional obligation of the Company as on March 31, 2006 amounting to Rs 21.37 Millions, net of deferred tax (Rs 10.84 Millions), has in accordance with the transitional provisions of AS -15 been debited to the retained earnings.
- Summary of Investor Complaints
Opening : Nil , Received during the quarter : -- 2 , Resolved : -- 2 ,Closing : Nil
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 27th July 2006 |
Sd/-
N.PRASAD
Executive Chairman
|
|
|
